Browse the evidence

Tirzepatide and semaglutide exceeded 10% total body weight loss and showed the most favorable glycaemic effects.

Tirzepatide and semaglutide may be prioritized for patients needing significant weight loss and glycaemic control.

Orforglipron treatment resulted in significant improvements in waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels compared to placebo.

Orforglipron may improve several cardiovascular and metabolic risk factors in obese adults.

In comparisons between intermittent fasting strategies, alternate day fasting lowered total cholesterol, triglycerides, and non-high density lipoprotein compared with time restricted eating.

Alternate day fasting may improve lipid profiles more effectively than time restricted eating.

The percentage of patients who had a glycated hemoglobin level of 6.5% or less was significantly higher in the cagrilintide-semaglutide group compared to the placebo group.

This treatment may significantly improve glycemic control in patients with type 2 diabetes.

Lifestyle modification remains the cornerstone of MASLD/MASH management alongside semaglutide.

Practitioners should emphasize lifestyle changes in addition to pharmacotherapy for optimal management.

Tirzepatide exhibited favorable effects on glycemic control, with reductions in HbA1c levels ranging from 20.4 mmol/mol with the 5 mg dose to 28.2 mmol/mol with the 15 mg dose.

Tirzepatide may improve glycemic control in patients with T2DM.

Body composition improved with losses in fat mass and gains in overall proportion of lean muscle and skeletal muscle.

Practitioners can expect improvements in body composition with semaglutide treatment.

Evidence-based nutritional and lifestyle strategies are crucial for effective GLP-1 treatment.

Clinicians should integrate nutritional and lifestyle interventions to enhance GLP-1 treatment outcomes.

Exercise is a well-established measure to prevent or mitigate the adverse consequences of obesity.

Encouraging exercise can be a key strategy in obesity management.

Tirzepatide-associated improvements in cardiometabolic risk factors are positively related to the degree of weight reduction.

Weight reduction through tirzepatide can lead to significant improvements in cardiometabolic health.

Improvements in triglycerides, HDL cholesterol, LDL cholesterol, and non-HDL cholesterol were primarily observed after weight reductions greater than 10%.

Targeting a weight reduction of over 10% may be necessary for significant improvements in lipid profiles.

The steepest improvements in cardiometabolic risk factors occurred between less than 5% and less than 20% weight reduction.

Practitioners should note that even modest weight loss can lead to significant health improvements, particularly within the 5-20% range.

Tirzepatide significantly reduces body mass index, waist circumference, blood pressure, and atherosclerotic cardiovascular disease risk.

Tirzepatide may improve overall cardiometabolic health in non-diabetic obese patients.

Patients in the semaglutide group experienced greater weight loss compared to the control group (−8.2% vs. −4.6%; P <0.001).

Semaglutide may be effective for weight management in patients post-ablation.

GLP-1 receptor agonist patients experienced greater weight loss (7.8 kg) compared to controls (0.5 kg), with statistical significance (p<0.001).

Weight management strategies may be more effective in patients using GLP-1 receptor agonists.

Modern dual and triple agonists achieve surgical-level metabolic benefits, redefining diabetes and obesity care.

These agonists may offer new treatment options for diabetes and obesity.

Endoscopic sleeve gastroplasty (ESG) has demonstrated durable weight loss, favorable safety, and superior cost-effectiveness compared to pharmacotherapy alone.

Practitioners may consider ESG as a viable option for patients seeking effective weight loss.

Semaglutide treatment resulted in significant reductions in body mass index (BMI), waist circumference, and HbA1c.

Practitioners can consider semaglutide as an effective treatment for reducing BMI and improving glycemic control in obese T2DM patients.

The management of MASLD in patients with T2D includes dietary and behavioral management, pharmacological treatment, and bariatric procedures.

Practitioners should consider a comprehensive management approach for diabetic patients with MASLD.

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) decreased from 82.6% to 30.4% after treatment with semaglutide.

Semaglutide may significantly improve liver health in patients with type 1 diabetes and MASLD.

Lifestyle intervention combined with older obesity medications is associated with approximately 5%-10% weight loss.

Combining lifestyle changes with medications can enhance weight loss outcomes for patients.

GLP-1 analogs have shown efficacy in improving weight loss and cardiovascular risk factors.

Practitioners may consider GLP-1 analogs as a treatment option for weight management in menopausal women.

Lifestyle modification can provide glycemic benefits to prevent type 2 diabetes (T2D) and its comorbidities.

Practitioners should encourage lifestyle modifications as a standard approach to prevent T2D.

Soy isoflavones can significantly contribute to lowering metabolic risk and affect hormonal balance in women with PCOS.

Incorporating soy isoflavones may be beneficial for women with PCOS in managing metabolic and hormonal issues.